Back to Journals » OncoTargets and Therapy » Volume 10

Low expression of DAB2IP predicts an unfavorable prognosis in human bladder carcinoma

Authors Zheng L, Chen K, Zhu L, Su D, Cheng G

Received 21 July 2017

Accepted for publication 6 November 2017

Published 29 November 2017 Volume 2017:10 Pages 5719—5726


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Akshita Wason

Peer reviewer comments 3

Editor who approved publication: Prof. Dr. Geoffrey Pietersz

Linfeng Zheng,1,* Kaiyan Chen,2,* Liang Zhu,1 Dan Su,1 Guoping Cheng1

1Department of Pathology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People’s Republic of China; 2Department of Medical Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, People’s Republic of China

*These authors contributed equally to this work

Abstract: The DOC-2/DAB2 interactive protein (DAB2IP) is a novel member of the Ras GTPase-activating protein family, and its downregulation is an unfavorable prognostic factor in several human malignancies. In this study, we retrospectively analyzed clinicopathological features, outcomes, and DAB2IP expression in 77 patients with urothelial carcinoma of the bladder (UCB). Expression of DAB2IP and p-STAT3 was examined in tumors and in matched adjacent non-cancerous tissues, using immunohistochemistry. We found a marked reduction in the expression of DAB2IP in UCB specimens, which was significantly associated with advanced pathological stage (P=0.037), high pathological grade (P=0.016), and muscle invasion (P=0.004). Moreover, multivariate analysis identified DAB2IP as an independent prognostic factor of cancer-specific survival (hazard ratio [HR] =0.23, 95% confidence interval [CI] =0.07–0.78, P=0.018). Most importantly, DAB2IP was negatively correlated with p-STAT3 expression (P=0.009), which predicted a shorter overall survival in patients with UCB (HR =2.68, 95% CI =1.63–6.99, P=0.044). In conclusion, downregulation of DAB2IP is associated with features of biologically aggressive UCB and may be a promising biomarker in patients after radical cystectomy.

Keywords: bladder urothelial carcinoma, DAB2IP, therapy targets, prognosis

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]